COVID-19 Vaccine Of Pfizer/BioNTech Receive UK Approval For EUA

UK COVID-19 Vaccine

The COVID-19 pandemic can come to an end only if scientists discover suitable treatments, for example, vaccination. Across the globe, with the great efforts of scientists and researchers, with the help of pharmaceutical and biotechnological companies and research institutions, various vaccine formations occur.

Clinical trials up to phase 3 also support the safety and efficacy profile of vaccines. But these vaccines need FDA approval before prescribing them for emergency use worldwide. However, the national drug regulatory authorities of various countries can approve vaccine usage within a specific country.

ALSO READ: mRNA COVID-19 Vaccine – An Innovation In Vaccination

Companies Developing The Coronavirus Vaccine

Coronavirus vaccine formulated by Pfizer and BioNTech is safe as well as effective. Similarly, coronavirus vaccines made by Moderna and Gilead Sciences are in the process of formation. But Moderna-COVID-19-vaccine has filed for emergency use approval by the FDA as it is more than ninety percent effective. 

Other companies that are working on the formation of coronavirus vaccines include Glaxo Smith Kline, Heat Biologics Inc., Inovio Pharmaceuticals, and Johnsons and Johnsons. A few more companies include Novavax Inc. and Regeneron Pharmaceuticals. Many other big companies are in the race to form effective and safe coronavirus vaccines at an affordable cost for users. 

However, which company will receive approval for market and emergency use authorization (EUA) depends upon the efficacy profile, bioavailability, safety, effectiveness, and accuracy of the vaccine.

UK Is The First Country To Approve Use Of COVID-19 Vaccine

UK regulators have given authorization for emergency usage of coronavirus-vaccine, which Pfizer and BioNTech developed. Following the emergency-use-authorization, Health Secretary Matt Hancock announced on Wednesday that the vaccine would be available by next week. 

Considering the data analysis of phase three trial of Pfizer/BioNTech coronavirus vaccine that indicates 95% effectiveness in preventing the COVID-19 infection, UK regulators permit its usage. The vaccine acts in the same way in older adults and young adults. 

Moreover, the vaccine has no side effects. The vaccine will likely improve the quality of life for millions of people in the United Kingdom. Apart from individual-benefits, vaccines will help indirectly in improving the financial state of the country.

How Many Doses will the UK Government Get In First Order?

Health secretary Matt Hancock, while telling the BBC, said that the United Kingdom ordered 40 million doses of coronavirus-vaccine from which 20 million people can benefit. 2 vaccine doses are essential for one individual to develop immunization against coronavirus. 

Out of the 40 million doses, 800,000 doses of COVID-19-vaccine will be available next week. Yet people need to wait until the National Health Institute contacts them. Furthermore, many more vaccine-doses will be reaching the UK in December. However, bulk dose delivery will occur in the upcoming year. The first to receive vaccinations are seniors in nursing homes and staff members in nursing homes. Then comes older people over the age of 80 years, and other healthcare workers. 

The Next Summer

According to Matt Hancock, 2020 has been awful, but 2021 will be better as from spring, from Easter onwards, things are going to become better. Further, he adds that everyone will be able to enjoy the coming summer of 2021.

ALSO READ: For COVID-19 Treatment Remdesivir Is Unnecessary, Says WHO 

The prime minister of the United Kingdom, Boris Johnson, shares his joy via Twitter over the news of the emergency use authorization of Pfizer/BioNTech COVID-19-vaccine. According to him, the decision is fantastic as the vaccine will not only help in protection against coronavirus. But also, allow us to get back on track and improve the economy of the UK. 

Although the Pfizer/BioNTech vaccine receives approval for emergency use in the UK, the FDA is still to decide on approving it later this month after a meeting of its advisory committee.

Adeena Tariq Lari
The author is a graduate of dental surgery from the Dow University Health Sciences, Karachi. She has an academic background in content writing as well as English literature, giving her an edge in the field. Adeena is always curious about physical and mental health. She is always passionate about research and delivering high-quality reliable content to users.